Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Study identifies epigenetic events critical to cancer cell survival

Study identifies epigenetic events critical to cancer cell survival

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Ponatinib offers new hope in drug-resistant leukemia

Ponatinib offers new hope in drug-resistant leukemia

Study provides important data about fertility window of women with childhood cancer

Study provides important data about fertility window of women with childhood cancer

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Disabling ItpkB enzyme improves function of Natural Killer cells

Disabling ItpkB enzyme improves function of Natural Killer cells

Trovagene develops first molecular diagnostic test to detect KRAS mutations from urine samples

Trovagene develops first molecular diagnostic test to detect KRAS mutations from urine samples

Researchers aim to improve feeling of 'walking on marbles' for arthritis patients

Researchers aim to improve feeling of 'walking on marbles' for arthritis patients

Researchers discover molecular basis for potential cancer preventive effects of vitamin D

Researchers discover molecular basis for potential cancer preventive effects of vitamin D

Elsevier announces launch of Leukemia Research Reports journal

Elsevier announces launch of Leukemia Research Reports journal

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Study to discover exactly how intravenous immune globulin treatments work

Study to discover exactly how intravenous immune globulin treatments work

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.